

## Larotaxel

## Chemical Properties

CAS No. : 156294-36-9


Formula: C<sub>45</sub>H<sub>53</sub>NO<sub>14</sub>

Molecular Weight: 831.9

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

|               |  |
|---------------|--|
| Description   | Larotaxel (XRP9881) is a taxane analogue with anticancer activity that promotes tubulin assembly and stabilizes microtubules, inducing apoptosis. It crosses the blood-brain barrier and has a higher affinity for Docetaxel than P-glycoprotein 1, making it useful for studying breast and bladder cancer. |
| Targets(IC50) | Apoptosis,P-gp   |

## Solubility Information

|            |  |
|------------|--|
| Solubility | DMSO: 50 mg/mL (60.1 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

## Preparing Stock Solutions

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 1.2021 mL | 6.0103 mL | 12.0207 mL |
| 5 mM  | 0.2404 mL | 1.2021 mL | 2.4041 mL  |
| 10 mM | 0.1202 mL | 0.601 mL  | 1.2021 mL  |
| 50 mM | 0.024 mL  | 0.1202 mL | 0.2404 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Zatloukal P, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. *J Thorac Oncol.* 2008 Aug;3(8):894-901.

Morris PG, et al. Novel anti-tubulin cytotoxic agents for breast cancer. *Expert Rev Anticancer Ther.* 2009 Feb;9(2):175-85.

Diéras V, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. *Ann Oncol.* 2008 Jul;19(7):1255-60.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481